
Regeneron’s Eylea fails combination study endpoint
pharmafile | October 3, 2016 | News story | Research and Development, Sales and Marketing | Eylea, Regeneron
Regeneron has announced that its eye drug Eylea (aflibercept) failed its primary endpoint in a mid-stage trial investigating its effectiveness for treating wet age-related macular degeneration (AMD) when used in combination with rinucumab.
The 500-patient CAPELLA study found that the combination therapy was not as effective in treating AMD as Eylea alone; top-line results showed that both one and two doses of the combination therapy did not demonstrate an improvement in best corrected visual acuity (BCVA) at 12 weeks according to the Early Treatment Diabetic Retinopathy Scale. The combination treatment also did nothing to improve anatomic endpoints such as reduction in retinal thickness or resolution of sub-retinal hyper-reflective material.
The study will continue with data analysed again at 28 and 52 weeks.
Regeneron CSO George Yancopoulos remarked that “[we] look forward to the results of our ongoing combination studies of [Eylea] and nesvacumab, an anti-angiopoietin 2 antibody, for which the preclinical data is more supportive.”
AMD accounts for nearly half of all cases of blindness in the developed world and usually affects the elderly.
Regeneron’s shares fell 3.6% following the news.
Matt Fellows
Related Content

Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …

Dupixent improves symptoms in patients with skin of colour, study shows
Sanofi and Regeneron have announced results from the collaborative phase 4 DISCOVER study, presented at …

Dupixent approved as first biologic medicine in Japan for COPD patients
The Ministry of Health, Labour and Welfare in Japan has authorised marketing and manufacturing of …






